Literature DB >> 12429239

Pathologic myopia: where are we now?.

Yasuo Tano1.   

Abstract

PURPOSE: To describe current concepts and available treatments for pathologic myopia.
DESIGN: Review of experimental and clinical studies.
METHODS: The demography, natural history, medical and surgical treatments for choroidal neovascular membrane, vitreoretinal interface disorders and future strategies for pathologic myopia are reviewed.
RESULTS: Several medical and surgical modalities are currently available to treat various complications of pathologic myopia. Macular translocation appears to stabilize or improve visual function in many eyes with choroidal neovascularization.
CONCLUSION: Newer strategies are emerging to better ameliorate or prevent the complications of pathologic myopia.

Entities:  

Mesh:

Year:  2002        PMID: 12429239     DOI: 10.1016/s0002-9394(02)01883-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  42 in total

1.  Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery.

Authors:  W-M Chan; D S C Lam; D T L Liu; T-H Wong; K S C Yuen
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

3.  Thermomechanical stability of sclera after glyceraldehyde crosslinking.

Authors:  Gregor Wollensak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-09-18       Impact factor: 3.117

4.  Ocular blood flow measurements in healthy human myopic eyes.

Authors:  Alexandra Benavente-Pérez; Sarah L Hosking; Nicola S Logan; David C Broadway
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-26       Impact factor: 3.117

5.  [Acute visual deterioration after "alternative therapy" in Russia].

Authors:  M Pavlidis; T Stupp; T F Büchner; H Gerding
Journal:  Ophthalmologe       Date:  2005-09       Impact factor: 1.059

Review 6.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

7.  How blinding is pathological myopia?

Authors:  S-M Saw
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

8.  Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Ariko Kojima; Kyoko Ohno-Matsui; Satoshi Teramukai; Yoko Ishihara; Noriaki Shimada; Takeshi Yoshida; Yoshiharu Sugamoto; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

9.  Optical coherence tomography to monitor photodynamic therapy in pathological myopia.

Authors:  A García-Layana; A Salinas-Alamán; M J Maldonado; C Sainz-Gómez; A Fernández-Hortelano
Journal:  Br J Ophthalmol       Date:  2006-02-07       Impact factor: 4.638

10.  Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia.

Authors:  Faik Gelisken; Werner Inhoffen; Alexander Hermann; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-17       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.